ALERGO295 Allergy Blood Test

ALERGO295 Allergy Blood Test is a broad laboratory assessment that measures allergen-specific immunoglobulin E, known as specific IgE, against 295 allergen targets from a single blood sample. It combines allergen extracts with individual molecular components to provide a detailed sensitization profile covering common inhaled allergens, foods, animal allergens, molds, insect venoms, latex, and other potential triggers.

The test may be considered when symptoms suggest an IgE-mediated allergy but the relevant trigger remains uncertain, when several allergens are suspected, or when previous testing has produced complex or apparently conflicting results. It can support the assessment of seasonal, environmental, food-related, respiratory, eye, and skin symptoms, but the findings must always be interpreted together with the person’s medical history and reactions after real-life exposure.

What ALERGO295 measures

Specific IgE antibodies are produced when the immune system becomes sensitized to a particular allergen. Unlike total IgE, which reflects the overall amount of IgE in the blood, specific IgE testing looks for antibodies directed against defined allergen sources or individual allergenic proteins.

The ALERGO295 profile examines 295 targets consisting of 117 allergen molecules and 178 allergen extracts from 123 allergen sources. The tested groups include:

• house dust mites, other arthropods, and insects
• tree, grass, and weed pollens
• animal-derived allergens
• molds and fungi
• foods of animal and plant origin
• bee and wasp venoms
• latex

An allergen extract contains a mixture of proteins from one source, such as birch pollen, peanut, milk, or cat dander. A molecular component is an individual protein within that source. Examining both levels can provide more detail than testing an extract alone.

Symptoms that may lead to allergy testing

Allergy testing may be discussed when symptoms repeatedly appear after exposure to pollen, dust, animals, certain foods, latex, insect stings, or another suspected trigger. Relevant patterns can include sneezing, a runny or blocked nose, itchy, red and watery eyes, coughing, wheezing or shortness of breath, and a rash or itchy skin.

The test may also be useful when symptoms occur in several organ systems, vary by season or location, or follow foods that are difficult to connect with a single allergen. Symptoms alone cannot establish an allergy because infections, irritation, asthma, skin conditions, food intolerance, and other medical problems can produce similar complaints.

Molecular components and cross-reactivity

Molecular allergology helps distinguish sensitization to a primary allergen source from cross-reactivity caused by structurally similar proteins. Cross-reactivity occurs when IgE produced against one allergenic protein also binds to a related protein in another source.

For example, a person sensitized to certain birch pollen proteins may also have positive findings for related proteins in apple, pear, hazelnut, or other plant foods. This pattern does not necessarily mean that each positive food result represents a separate primary food allergy. Component-level information can help a qualified clinician determine whether multiple positive findings may originate from one underlying sensitization pattern.

Cross-reactive proteins are found in several allergen families, including pollen and plant foods, different animal species, latex and certain fruits, or related insect venoms. The clinical importance of each pattern depends on actual exposure, symptoms, the molecular component involved, and the complete medical history.

Sensitization is not the same as clinical allergy

A positive specific IgE result shows sensitization, meaning that IgE antibodies recognizing the tested allergen were detected. It does not automatically prove that exposure causes symptoms or that the person has a clinically relevant allergy.

Some sensitizations remain asymptomatic, while others correspond closely with allergic reactions. The concentration of specific IgE may contribute to the assessment, but it does not independently determine whether symptoms will occur or how severe a reaction will be.

The test also cannot reliably predict future allergic reactions. A positive result must not be interpreted as evidence that a reaction will necessarily develop later. Clinical relevance is assessed by comparing the result with previous exposures, symptom timing, tolerated foods, environmental patterns, and, when needed, additional allergological evaluation.

How the test is performed

Step 1: Review of symptoms and suspected triggers

Before testing, it is useful to record the symptoms, when they occur, possible exposures, seasonal patterns, foods that are tolerated or suspected, previous reactions, medication use, and earlier allergy findings. A broad panel can identify many sensitizations, but this background information is essential for distinguishing clinically relevant results from findings without symptoms.

Step 2: Blood sample collection

One tube of blood is collected. Serum from the sample is used for the laboratory analysis. The test does not expose the person to allergens on the skin or through ingestion.

Step 3: Specific IgE analysis

The sample is analyzed for specific IgE against the included allergen extracts and molecular components. The resulting profile can show negative findings, individual sensitizations, or groups of related positive results that may indicate cross-reactivity.

Step 4: Report and professional interpretation

The laboratory report presents the identified specific IgE findings and their measured values. Professional interpretation considers the complete pattern rather than treating every positive result as a separate allergy.

Preparation before sampling

Fasting is not required. Antihistamines and corticosteroids do not need to be stopped specifically for this blood test because the analysis measures circulating antibodies rather than a reaction in the skin. Medications should not be changed without instructions from the treating physician.

Before sampling, the patient should provide relevant information about current medication, previous severe reactions, diagnosed allergies, asthma, skin conditions, pregnancy, fainting during blood collection, or difficulty obtaining blood samples.

Understanding the results and limitations

The report can support decisions about which allergens deserve closer clinical attention and whether a pattern is more compatible with primary sensitization or cross-reactivity. It may also help determine whether additional targeted testing, an allergology consultation, supervised challenge testing, or another diagnostic pathway is appropriate.

ALERGO295 assesses IgE-mediated sensitization. It does not diagnose food intolerance, non-IgE-mediated reactions, contact dermatitis, medication side effects, or every possible cause of respiratory, digestive, eye, or skin symptoms. Negative results do not exclude all forms of allergy.

Foods should not be removed from the diet solely because of an isolated positive result, especially when they are eaten without symptoms. Unnecessary avoidance can reduce dietary variety and may create nutritional problems. Decisions about allergen avoidance, emergency medication, or immunotherapy require an individualized medical assessment.

A blood allergy test is not an emergency assessment. Sudden breathing difficulty, swelling of the tongue or throat, fainting, rapidly spreading hives, or severe symptoms after food, medication, latex, or an insect sting require urgent medical care.

To arrange the test through ZagrebMed, send a short description of the symptoms, suspected triggers, previous reactions, current medication, and any earlier allergy results. This information can help clarify whether a broad molecular panel or a more targeted evaluation is the more appropriate next step.